한빛사논문
- 조회282
Kyong-Ah Yoon 1,12, Youngwook Kim 2,12, So-Youn Jung 2,3,12, Jin-Sun Ryu 4,5, Kyung-Hee Kim 2,6, Eun-Gyeong Lee 3, Heejung Chae 7,8, Youngmee Kwon 3, Jaegil Kim 9, Jong Bae Park 2,13,* and Sun-Young Kong 2,10,11,13,*
1Department of Biochemistry, College of Veterinary Medicine, Konkuk University, Seoul, Korea.
2Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
3Center for Breast Cancer, National Cancer Center, Goyang, Korea.
4Division of Translational Science, Research Institute, National Cancer Center, Goyang, Korea.
5Laboratory Animal Research Facility, Research Institute, National Cancer Center, Goyang, Korea.
6Proteomics Core Facility, Research Core Center, Research Institute, National Cancer Center, Goyang, Korea.
7Cancer Data Center, Control Institute, National Cancer Center, Goyang, Korea.
8Division of Medical Oncology, Hospital, National Cancer Center, Goyang, Korea.
9GlaxoSmithKline, Waltham, MA, USA.
10Department of Laboratory Medicine, Research Institute, National Cancer Center Korea, Goyang, Korea.
11Department of Targeted Therapy Branch, Research Institute, National Cancer Center, Goyang, Korea.
12These authors contributed equally: Kyong-Ah Yoon, Youngwook Kim, So-Youn Jung.
13These authors jointly supervised this work: Jong Bae Park, Sun-Young Kong.
*Corresponding authors: correspondence to Jong Bae Park or Sun-Young Kong
Abstract
Early-onset breast cancer is known for its aggressive clinical characteristics and high prevalence in East Asian countries, but a comprehensive understanding of its molecular features is still lacking. In this study, we conducted a proteogenomic analysis of 126 treatment-naïve primary tumor tissues obtained from Korean patients with young breast cancer (YBC) aged ≤40 years. By integrating genomic, transcriptomic, and proteomic data, we identified five distinct functional subgroups that accurately represented the clinical characteristics and biological behaviors of patients with YBC. Our integrated approach could be used to determine the proteogenomic status of HER2, enhancing its clinical significance and prognostic value. Furthermore, we present a proteome-based homologous recombination deficiency (HRD) analysis that has the potential to overcome the limitations of conventional genomic HRD tests, facilitating the identification of new patient groups requiring targeted HR deficiency treatments. Additionally, we demonstrated that protein–RNA correlations can be used to predict the late recurrence of hormone receptor-positive breast cancer. Within each molecular subtype of breast cancer, we identified functionally significant protein groups whose differential abundance was closely correlated with the clinical progression of breast cancer. Furthermore, we derived a recurrence predictive index capable of predicting late recurrence, specifically in luminal subtypes, which plays a crucial role in guiding decisions on treatment durations for YBC patients. These findings improve the stratification and clinical implications for patients with YBC by contributing to the optimal adjuvant treatment and duration for favorable clinical outcomes.
논문정보
- Research article
- 2024년 11월 (BRIC 등록일 2024-11-08)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
